References
- Amane HS, Burte NP. (2011). A comparative study of dalteparin and unfractionated heparin in patients with unstable angina pectoris. Indian J Pharmacol 43:703–6
- Collignon F, Frydman A, Caplain H, et al. (1995). Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 73:630–40
- Cook D, Meade M, Guyatt G, et al. (2011). Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 364:1305–14
- de Jonge E, Levi M, Stoutenbeek CP, van Deventer SJ. (1998). Current drug treatment strategies for disseminated intravascular coagulation. Drugs 55:767–77
- Fareed J, Jeske W, Hoppensteadt D, et al. (1998). Low-molecular-weight heparins: pharmacologic profile and product differentiation. Am J Cardiol 82:3L–10L
- Francis CW, Kessler CM, Goldhaber SZ, et al. (2015). Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 13:1028–35
- Griffiths GO, Burns S, Noble SI, et al. (2009). FRAGMATIC: a randomised phase III clinical trial investigating the effect of fragmin added to standard therapy in patients with lung cancer. BMC Cancer 9:355
- Hammerstingl C. (2008). Monitoring therapeutic anticoagulation with low molecular weight heparins: is it useful or misleading? Cardiovasc Hematol Agents Med Chem 6:282–6
- Hirsh J, Bauer KA, Donati MB, et al. (2008). Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(6 Suppl):141S–59S
- Hirsh J, Levine MN. (1992). Low molecular weight heparin. Blood 79:1–17
- Laposata M, Green D, Van Cott EM, et al. (1998). College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 122:799–807
- Li G, Cook DJ, Levine MA, et al. (2015). Competing risk analysis for evaluation of dalteparin versus unfractionated heparin for venous thromboembolism in medical-surgical critically ill patients. Medicine (Baltimore) 94:e1479
- Moayer A, Mohebali N, Razmkon A. (2016). Incidence of deep vein thrombosis in patients undergoing degenerative spine surgery on prophylactic dalteparin; a single center report. Bull Emerg Trauma 4:38–42
- Ofosu FA. (2012). A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins. Thromb Haemost 107:201–14
- Park D, Southern W, Calvo M, et al. (2016). Treatment with dalteparin is associated with a lower risk of bleeding compared to treatment with unfractionated heparin in patients with renal insufficiency. J Gen Intern Med 31:182–7
- Samama MM, Poller L. (1995). Contemporary laboratory monitoring of low molecular weight heparins. Clin Lab Med 15:119–23
- Spinler SA, Inverso SM, Cohen M, et al. (2003). Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146:33–41
- Warkentin TE, Levine MN, Hirsh J, et al. (1995). Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332:1330–5